DOCSLIB.ORG

What, How, Where, When, and Why Antibiotics 101

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
What, How, Where, When, and Why Antibiotics 101 Antibiotics - What, How, Where, When, and Why Antibiotics 101 Paul Dorr NCSU College of Veterinary Medicine Population Health and Pathobiology North Carolina State University Introduction: Antibiotics and antimicrobials are very important in the treatment of bacterial infections in both humans and animals. Of equal importance is the judicious use of these substances. In today’s swine industry, producers must be very aware as to what exactly they are treating their animals with, and what they are treating their animals for. One cannot judiciously use antimicrobials without a basic understanding of what they are, how they work, where and when one uses them, and why they are used. Furthermore, the recognition of certain antimicrobials and other therapeutic agents that should never be found on any swine farm is essential knowledge that producers must have. So, what is an antibiotic, and what is the difference between an antibiotic and an antimicrobial? According to the FDA an antibiotic is defined as, “A chemical substance produced by a microorganism. It has the capacity, in dilute solutions, to inhibit the growth of or to kill other microorganisms.” (1) So, essentially antibiotics are produced by various types of bacteria and fungi. The following is an example of some common antibiotics and their bacterial/fungal origins. –Tetracycline - Streptomyces aureofaciens –Neomycin - Streptomyces fradiae –Lincomycin - Streptomyces lincolnensis –Ceftiofur - Cephalosporium acremonium –Gentamicin - Micromonaspora purpurea (2) An antimicrobial may be defined as a compound that inhibits the growth or kills microorganisms. This includes antibiotics in addition to various compounds that are not of microorganism origin.(1) This definition would include synthetic products such as sulfas, quinolones, and nitrofurans. This leaves us with the next question, how do these substances work? Antibiotics are usually grouped according to their method of action and their spectrum of activity. There are 5 general methods of action (MOA) that antibiotics exhibit. These include inhibition of ribosomal protein synthesis, inhibition of DNA replication, alteration of metabolism, disruption of cell membrane function, and disruption of cell wall synthesis. (2,3) Also, antibiotics may have either a broad or narrow spectrum of activity. Simply put, a broad spectrum antibiotic is an antibiotic that is effective against both gram positive and gram negative bacteria. A narrow spectrum antibiotic is an antibiotic that is effective only for a limited or specific type of bacteria.(1) The different classes of antibiotics, their spectrum of activity, and various general methods of action are summarized in Table 1. Antibiotic class Antibiotic name examples Spectrum Method of action Narrow to Penicillins Potassium Pen G, Ampicillin, Amoxicillin broad disruption of cell wall synthesis Cephalosporins Ceftiofur Broad disruption of cell wall synthesis Aminoglycosides Streptomycin, Neomycin, Gentamycin Narrow inhibition of ribosomal protein synthesis Spectinomycin Spectinomycin Broad inhibition of ribosomal protein synthesis Chloramphenicol Florfenicol Broad inhibition of ribosomal protein synthesis Tetracyline, Oxytetracycline, Tetracyclines Chlorteteracycline Broad inhibition of ribosomal protein synthesis Macrolides Erythromycin, Tylosin, Tilmicosin Narrow inhibition of ribosomal protein synthesis Lincosamides Lincomycin Narrow inhibition of ribosomal protein synthesis Polymyxin Polymyxin B Narrow disruption of cell membrane function Bacitracin Bacitracin Narrow disruption of cell wall synthesis Tiamulin Tiamulin Narrow alteration of metabolism Sulfas Sulfathiazole, Sulfamethazine, Sulfadiazine Broad alteration of metabolism Table 1. Summary of antibiotic class, name, spectrum of activity and method of action of antibiotics commonly used in swine production. (2,4,5) Where then, do we use these substances, or more succinctly, how are they administered? To answer this question, a few things must be considered. First, WHAT DOES THE LABEL SAY! This is by far the most important consideration when administering antibiotics. Various antibiotics may be administered a number of different ways and have different withdrawal times which are indicated on the label. The various routes of administration that may be listed on the labels of different products include oral (dosing pump, water, feed), intravenous, intramuscular, and subcutaneous. The second aspect that must be considered is the bioavailability of the antibiotic given the route of administration and antibiotic type. For example, potassium penicillin G has a bioavailability of approximately 5% when administered orally (i.e. 5% is absorbed into the blood and the rest is excreted in the feces). So this would not be a good choice of antibiotic when trying to treat a systemic infection like Strep . even though the bacteria may be susceptible. When do we use these substances? Obviously when the pigs are sick. As with the label information, there are some important points to consider. First, antibiotics are not virusidial, i.e. they will have no direct effect on killing viral agents like PRRS, SIV, and TGE. Second, they are not a silver bullet for general illness or disease of unknown etiology. You have to know what you are up against. Third, culture and sensitivity data must be utilized. You have to know what works. Fourth, what kind of infection is it, respiratory, enteric, or systemic? All of these factors play a part when considering when to use antibiotics and which ones to use. Now we must consider why the label must be followed. A lot of research has been done to determine the optimal blood concentration or bioavailability at the site of infection that these antibiotics must obtain in order to be effective against the bacteria they are labeled to protect against. The effects of underdosing and overdosing will both have a detrimental effect on the health on the pig. Underdosing may provide an opportunity for bacterial proliferation when blood concentrations of the antibiotic are low, as seen in Figure 1. Antibiotic Blood Levels Bacterial growth will 8 occur here Blood level of 6 antibiotic 4 Level 2 Minimum blood level of antibiotic Relative Blood Blood Relative 0 where bacteria are killed Hours 4 12 20 28 36 44 52 60 68 Figure 1. Relative antibiotic blood levels when patient is under dosed. Figure 2. Relative antibiotic blood levels with a correct dosing schedule. Antibiotic Blood Levels Blood level of antibiotic 10 8 6 Minimum blood 4 levels level of antibiotic 2 where bacteria Relativeblood are killed 0 Ho urs 4 12 20 28 36 44 52 60 68 Some possible ramifications of underdosing include, but are not limited to: having to treat the animal longer, persistence of infection (resulting in decreased ADG and FE), and selection and proliferation of resistant subpopulations of bacteria. Overdosing may result in toxicity which will affect various body systems depending on the agent. If the bacterial infection that is being treated is persisting beyond the scheduled treatment period, many things must be considered. First, the animal(s) may have a superinfection in which the bacteria overwhelm the antibiotic at the given dose and bodies own defenses cannot fight off the bacteria. Along these same lines the animal may be immunocompromised as is the case with PRRS infection. Other reasons include failure of the antibiotic to reach the site of infection, the pH of the tissues is to high or to low, the bacteria is resistant to the current therapy, an incorrect dose was used, the antibiotic is outdated, an incorrect route of administration was used, or the dosing schedule was altered. (3). Part of using antimicrobials judiciously includes knowing which ones not to use and being able to identify substances on the farm that are currently illegal for use in animals. Many of these substances have adverse human and animal health implications. Furthermore, a few products, which are listed below, are legal for use in some animals, but not in swine. Table 2 contains a list of products that should never be found on a swine farm. Substances That Should Never Be Found On A Swine Farm Chloramphenicol – aplastic anemia in humans Clenbuterol Diethylstilbesterol - (DES) carcinogenic Nitroimidazoles - (dimetridazole, ipromidazole) carcinogenic Nitrofurans - (nitrofurazone) carcinogenic, mutagenic Sulfonamides – There are some approved ones, check label Fluoroquinolones - (enrofloxacin - Baytril 100) Dipyrone!!! Glycopeptides - (Vancomycin) human Staph. aureus resistance concern Table 2. Substances that should never be found on a swine farm.(6) Judicious use of antimicrobials is of great importance in today’s production systems. Un-judicious use of these substances has both human and animal health implications and legal ramifications. The most important take home message is: Be Responsible! Treat the animals that need to be treated. Follow the directions on the label/prescription paying special attention to withdrawal time, dose, dosing schedule, spectrum of activity, and route of administration. Furthermore, always be aware of what is on your farm with regards to outdated product and products not approved for use in swine. Always consult your veterinarian with any questions regarding these issues. Following these simple guidelines concerning antimicrobial use will help to ensure a healthier hog out the door. Sources 1. Judicious Use of Antimicrobials for Pork Producers. Department of Health and Human Services, Public Health Service, Food and Drug Administration Center for Veterinary Medicine. Aug. 2001. 2. Plumb, DC. Veterinary Drug Handbook. Third Edition. Iowa State University Press. Ames, IA. 3. Berg, J. Pathogenic Bacteriology and Mycology in Veterinary Medicine. VM553 note set. University of Missouri – Columbia. Fall 2000. 4. Butaye, P, et. al. Influence of different medium components on the in vitro activity of the growth promoting antibiotic flavomycin against enterococci. Journal of Antimicrobial Chemotherapy (2000) 46, 713-716. 5. Compendium of Veterinary Products. 7 th Ed. Bayer. North American Compendiums, Ltd. 2003. 6. Drugs Prohibited From Extralabel Use In Food Animals. http://www.saanendoah.com/prohibiteddrugs.html . 2003 .
Load more

Recommended publications
  • First Case of Staphylococci Carrying Linezolid Resistance Genes from Laryngological Infections in Poland
    pathogens Article First Case of Staphylococci Carrying Linezolid Resistance Genes from Laryngological Infections in Poland Michał Michalik 1, Maja Kosecka-Strojek 2,* , Mariola Wolska 2, Alfred Samet 1, Adrianna Podbielska-Kubera 1 and Jacek Mi˛edzobrodzki 2 1 MML Medical Centre, Bagno 2, 00-112 Warsaw, Poland; [email protected] (M.M.); [email protected] (A.S.); [email protected] (A.P.-K.) 2 Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Kraków, Poland; [email protected] (M.W.); [email protected] (J.M.) * Correspondence: [email protected] Abstract: Linezolid is currently used to treat infections caused by multidrug-resistant Gram-positive cocci. Both linezolid-resistant S. aureus (LRSA) and coagulase-negative staphylococci (CoNS) strains have been collected worldwide. Two isolates carrying linezolid resistance genes were recovered from laryngological patients and characterized by determining their antimicrobial resistance patterns and using molecular methods such as spa typing, MLST, SCCmec typing, detection of virulence genes and ica operon expression, and analysis of antimicrobial resistance determinants. Both isolates were multidrug resistant, including resistance to methicillin. The S. aureus strain was identified as ST- 398/t4474/SCCmec IVe, harboring adhesin, hemolysin genes, and the ica operon. The S. haemolyticus strain was identified as ST-42/mecA-positive and harbored hemolysin genes. Linezolid resistance Citation: Michalik, M.; S. aureus Kosecka-Strojek, M.; Wolska, M.; in strain was associated with the mutations in the ribosomal proteins L3 and L4, and in Samet, A.; Podbielska-Kubera, A.; S.
    [Show full text]
  • MACROLIDES (Veterinary—Systemic)
    MACROLIDES (Veterinary—Systemic) This monograph includes information on the following: Category: Antibacterial (systemic). Azithromycin; Clarithromycin; Erythromycin; Tilmicosin; Tulathromycin; Tylosin. Indications ELUS EL Some commonly used brand names are: For veterinary-labeled Note: The text between and describes uses that are not included ELCAN EL products— in U.S. product labeling. Text between and describes uses Draxxin [Tulathromycin] Pulmotil Premix that are not included in Canadian product labeling. [Tilmicosin Phosphate] The ELUS or ELCAN designation can signify a lack of product Erythro-200 [Erythromycin Tylan 10 [Tylosin availability in the country indicated. See the Dosage Forms Base] Phosphate] section of this monograph to confirm availability. Erythro-Med Tylan 40 [Tylosin [Erythromycin Phosphate] General considerations Phosphate] Macrolides are considered bacteriostatic at therapeutic concentrations Gallimycin [Erythromycin Tylan 50 [Tylosin Base] but they can be slowly bactericidal, especially against Phosphate] streptococcal bacteria; their bactericidal action is described as Gallimycin-50 Tylan 100 [Tylosin time-dependent. The antimicrobial action of some macrolides is [Erythromycin Phosphate] enhanced by a high pH and suppressed by low pH, making them Thiocyanate] less effective in abscesses, necrotic tissue, or acidic urine.{R-119} Gallimycin-100 Tylan 200 [Tylosin Base] Erythromycin is an antibiotic with activity primarily against gram- [Erythromycin Base] positive bacteria, such as Staphylococcus and Streptococcus Gallimycin-100P Tylan Soluble [Tylosin species, including many that are resistant to penicillins by means [Erythromycin Tartrate] of beta-lactamase production. Erythromycin is also active against Thiocyanate] mycoplasma and some gram-negative bacteria, including Gallimycin-200 Tylosin 10 Premix [Tylosin Campylobacter and Pasteurella species.{R-1; 10-12} It has activity [Erythromycin Base] Phosphate] against some anaerobes, but Bacteroides fragilis is usually Gallimycin PFC Tylosin 40 Premix [Tylosin resistant.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Florfenicol Item No. 19458 CAS Registry No.: 73231-34-2 Formal Name: 2,2-dichloro-N-[(1S,2R)-1- (fluoromethyl)-2-hydroxy-2-[4- OH F (methylsulfonyl)phenyl]ethyl]-acetamide Synonym: SCH 25298 Cl MF: C12H14Cl2FNO4S FW: 358.2 N H Cl Purity: ≥98% S O UV/Vis.: λmax: 224 nm Supplied as: A crystalline solid OO Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Florfenicol is supplied as a crystalline solid. A stock solution may be made by dissolving the florfenicol in the solvent of choice, which should be purged with an inert gas. Florfenicol is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of florfenicol in these solvents is approximately 14, 50, and 30 mg/ml, respectively. Florfenicol is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, florfenicol should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Florfenicol has a solubility of approximately 0.03 mg/ml in a 1:30 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Florfenicol is a broad-spectrum fluorinated antibiotic and a derivative of thiamphenicol (Item No. 21357).1 It is active against human clinical isolates of enteric bacteria, including E. coli, Klebsiella, Enterobacter, 2 Citrobacter, P. mirabilis, and Salmonella (MIC50s = 6.3-12.5 µg/ml). Florfenicol is also active against clinical isolates of various bovine and porcine respiratory tract pathogens, including P.
    [Show full text]
  • Antimicrobial Susceptibility and Association with Toxin Determinants in Clostridium Perfringens Isolates from Chickens
    microorganisms Article Antimicrobial Susceptibility and Association with Toxin Determinants in Clostridium perfringens Isolates from Chickens 1, 1, 1 1 2 Bai Wei y, Se-Yeoun Cha y, Jun-Feng Zhang , Ke Shang , Hae-Chul Park , JeongWoo Kang 2 , Kwang-Jick Lee 2, Min Kang 1,* and Hyung-Kwan Jang 1,* 1 Center for Poultry Diseases Control, Department of Veterinary Infectious Diseases and Avian Diseases, College of Veterinary Medicine and Jeonbuk National University, Iksan 54596, Korea; [email protected] (B.W.); [email protected] (S.-Y.C.); [email protected] (J.-F.Z.) [email protected] (K.S.) 2 Veterinary Drugs & Biologics Division, Animal and Plant Quarantine Agency (QIA), Gimcheon 39660, Korea; [email protected] (H.-C.P.); [email protected] (J.K.); [email protected] (K.-J.L.) * Correspondence: [email protected] (M.K.); [email protected] (H.-K.J.); Tel.: +82-63-850-0690 (M.K.); +82-63-850-0945 (H.-K.J.); Fax: +82-858-0686 (M.K.); +82-858-9155 (H.-K.J.) These authors contributed equally to this study. y Received: 25 October 2020; Accepted: 17 November 2020; Published: 19 November 2020 Abstract: The aim of the present study was to investigate variation in antimicrobial resistance in Clostridium perfringens (C. perfringens) isolated from chickens after withdrawal of antimicrobial growth promoters (AGPs); and to investigate the correlation between the presence of toxin genes (cpb2, netB, and tpeL) and antimicrobial resistance. Altogether, 162 isolates of C. perfringens were obtained from chickens displaying clinical signs of necrotic enteritis (n = 65) and from healthy chickens (n = 97) in Korea during 2010–2016.
    [Show full text]
  • Characterization of Florfenicol Resistance Genes in the Coagulase-Negative
    Characterization of orfenicol resistance genes in the coagulase-negative Staphylococcus (CoNS) isolates and genomic features of a multidrug- resistant Staphylococcus lentus strain H29 Chongyang Wu department of laboratory medicine,Sichuan University West China School of Public Health Xueya Zhang Wenzhou Medical University Jialei Liang Wenzhou Medical University Qiaoling Li Wenzhou Medical University Hailong Lin Wenzhou Medical University Chaoqing Lin Wenzhou Medical University Second Aliated Hospital Hongmao Liu Wenzhou Medical University Second Aliated Hospital Danying Zhou Wenzhou Medical University Wei Lu Wenzhou Medical University Zhewei Sun Wenzhou Medical University Xi Lin Wenzhou Medical University Hailin Zhang Wenzhou Medical University Second Aliated Hospital Keiwei Li Wenzhou Medical University Teng Xu Institute of translation medicine,Baotou central hospital Qiyu Bao ( [email protected] ) Wenzhou Medical University https://orcid.org/0000-0002-9550-8266 Junwan Lu Wenzhou Medical University Research Keywords: Coagulase-negative staphylococci, Staphylococcus lentus, orfenicol resistance genes, whole genome, comparative genomics analysis Posted Date: December 18th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-52544/v3 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on January 7th, 2021. See the published version at https://doi.org/10.1186/s13756-020-00869-5. 1 Characterization of florfenicol resistance genes
    [Show full text]
  • ARCH-Vet Anresis.Ch
    Usage of Antibiotics and Occurrence of Antibiotic Resistance in Bacteria from Humans and Animals in Switzerland Joint report 2013 ARCH-Vet anresis.ch Publishing details © Federal Office of Public Health FOPH Published by: Federal Office of Public Health FOPH Publication date: November 2015 Editors: Federal Office of Public Health FOPH, Division Communicable Diseases. Elisabetta Peduzzi, Judith Klomp, Virginie Masserey Design and layout: diff. Marke & Kommunikation GmbH, Bern FOPH publication number: 2015-OEG-17 Source: SFBL, Distribution of Publications, CH-3003 Bern www.bundespublikationen.admin.ch Order number: 316.402.eng Internet: www.bag.admin.ch/star www.blv.admin.ch/gesundheit_tiere/04661/04666 Table of contents 1 Foreword 4 Vorwort 5 Avant-propos 6 Prefazione 7 2 Summary 10 Zusammenfassung 12 Synthèse 14 Sintesi 17 3 Introduction 20 3.1 Antibiotic resistance 20 3.2 About anresis.ch 20 3.3 About ARCH-Vet 21 3.4 Guidance for readers 21 4 Abbreviations 24 5 Antibacterial consumption in human medicine 26 5.1 Hospital care 26 5.2 Outpatient care 31 5.3 Discussion 32 6 Antibacterial sales in veterinary medicines 36 6.1 Total antibacterial sales for use in animals 36 6.2 Antibacterial sales – pets 37 6.3 Antibacterial sales – food producing animals 38 6.4 Discussion 40 7 Resistance in bacteria from human clinical isolates 42 7.1 Escherichia coli 42 7.2 Klebsiella pneumoniae 44 7.3 Pseudomonas aeruginosa 48 7.4 Acinetobacter spp. 49 7.5 Streptococcus pneumoniae 52 7.6 Enterococci 54 7.7 Staphylococcus aureus 55 Table of contents 1 8 Resistance in zoonotic bacteria 58 8.1 Salmonella spp.
    [Show full text]
  • New Livestock Antibiotic Rules for California
    New Livestock Antibiotic Rules for California alifornia Senate Bill 27 was signed by Governor Brown on October 10, 2015 with an • MIADs may not be administered for purposes of Cimplementation date of January 1, 2018. It set promoting weight gain or improving feed effi ciency. aggressive, groundbreaking standards for antimicrobial drug use in California livestock and was supported by the • Livestock owners, including apiculturists, backyard poul- try owners, small livestock herd or fl ock owners, or hobby CVMA. farmers may only purchase and administer MIADs with a prescription from a California licensed veterinarian with a As of January 1, all medically important antimicrobial valid VCPR, unless intended to be fed to livestock which drugs (MIADs) used in livestock may only be obtained requires a veterinary feed directive. through a veterinary prescription or a veterinary feed directive pursuant to a valid veterinarian-client-patient • Feed stores will no longer sell MIADs over the counter relationship (VCPR). In order for a VCPR to be valid, and feed mills will no longer add MIADs to feed without the client must authorize the veterinarian to assume a veterinary feed directive (VFD) (the latter commenced responsibility for making medical judgments regarding in 2017 pursuant to federal regulations). the health of the animal and the veterinarian must assume this responsibility. The veterinarian must then have Many livestock owners are not accustomed to having a suffi cient knowledge of the animal(s) to initiate at least a veterinarian and have been purchasing MIADs at the feed general or preliminary diagnosis. This can only be done store. This is no longer an option and they may ask where through an in-person physical exam of the animal(s) or by they can get their prescription fi lled.
    [Show full text]
  • Phenotypic and Molecular Traits of Staphylococcus Coagulans Associated with Canine Skin Infections in Portugal
    antibiotics Article Phenotypic and Molecular Traits of Staphylococcus coagulans Associated with Canine Skin Infections in Portugal Sofia Santos Costa 1,* , Valéria Oliveira 1, Maria Serrano 1, Constança Pomba 2,3 and Isabel Couto 1,* 1 Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), Rua da Junqueira 100, 1349-008 Lisboa, Portugal; [email protected] (V.O.); [email protected] (M.S.) 2 Centre of Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477 Lisboa, Portugal; [email protected] 3 GeneVet, Laboratório de Diagnóstico Molecular Veterinário, Rua Quinta da Nora Loja 3B, 2790-140 Carnaxide, Portugal * Correspondence: [email protected] (S.S.C.); [email protected] (I.C.); Tel.: +351-21-3652652 (S.S.C. & I.C.); Fax: +351-21-3632105 (S.S.C. & I.C.) Abstract: Staphylococcus coagulans is among the three most frequent pathogens of canine pyoderma. Yet, studies on this species are scarce. Twenty-seven S. coagulans and one S. schleiferi, corresponding to all pyoderma-related isolations from these two species at two veterinary laboratories in Lisbon, Portugal, between 1999 and 2018 (Lab 1) or 2018 (Lab 2), were analyzed. Isolates were identified by the analysis of the nuc gene and urease production. Antibiotic susceptibility towards 27 antibiotics was evaluated by disk diffusion. Fourteen antibiotic resistance genes were screened by PCR. Isolates were typed by SmaI-PFGE. Two S. coagulans isolates (2/27, 7.4%) were methicillin-resistant (MRSC, mecA+) and four (4/27, 14.8%) displayed a multidrug-resistant (MDR) phenotype.
    [Show full text]
  • ESVAC 8Th Report. Sales of Veterinary Antimicrobial Agents in 30
    Sales of veterinary antimicrobial agents in 30 European countries in 2016 Trends from 2010 to 2016 Eighth ESVAC report An agency of the European Union Mission statement The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role • involves representatives of patients, healthcare professionals and other stakeholders in its work, to facilitate dialogue on The European Medicines Agency (hereinafter ‘the Agency’ issues of common interest; or EMA) is the European Union (EU) body responsible for coordinating the existing scientific resources put at its disposal • publishes impartial and comprehensible information about by Member States for the evaluation, supervision and medicines and their use; pharmacovigilance of medicinal products. • develops best practice for medicines evaluation and The Agency provides the Member States and the institutions supervision in Europe, and contributes alongside the Member of the EU and the European Economic Area (EEA) countries States and the EC to the harmonisation of regulatory with the best-possible scientific advice on any questions standards at the international level. relating to the evaluation of the quality, safety and efficacy of medicinal products for human or veterinary use referred to it in accordance with the provisions of EU legislation Guiding principles relating to medicinal products. • We are strongly committed to public and animal health. The founding legislation of the Agency is Regulation (EC) No • We make independent recommendations based on scien- 726/2004 of the European Parliament and the Council of 31 tific evidence, using state-of-the-art knowledge and March 2004 laying down Community procedures for the expertise in our field.
    [Show full text]
  • Data Management Subcommittee
    i ii iii WHO Library Cataloguing-in-Publication Data Report of the 2nd meeting of the WHO advisory group on integrated surveillance of antimicrobial resistance, Guelph, Canada, 5-7 June 2010. 1.Anti-infective agents - classification. 2.Anti-infective agents - adverse effects. 3.Drug resistance, microbial - drug effects. 4.Risk management. 5.Humans. I.World Health Organization. ISBN 978 92 4 150263 4 (NLM classification: QV 250) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e- mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Antimicrobial Susceptibility of Mycoplasma Bovis Isolates from Veal, Dairy and Beef Herds
    antibiotics Article Antimicrobial Susceptibility of Mycoplasma bovis Isolates from Veal, Dairy and Beef Herds 1,2, 1, 3 3 Jade Bokma * , Linde Gille y , Koen De Bleecker , Jozefien Callens , 2 1, 2, Freddy Haesebrouck , Bart Pardon z and Filip Boyen z 1 Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium; [email protected] (L.G.); [email protected] (B.P.) 2 Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium; [email protected] (F.H.); fi[email protected] (F.B.) 3 Animal Health Service-Flanders, Industrielaan 29, 8820 Torhout, Belgium; [email protected] (K.D.B.); jozefi[email protected] (J.C.) * Correspondence: [email protected] Present address: Clinical Department of Production Animals, Faculty of Veterinary Medicine, y University of Liège, Quartier Vallée 2 Avenue de Cureghem, 7D, 4000 Liège, Belgium. Bart Pardon and Filip Boyen should be considered joint senior author. z Received: 18 November 2020; Accepted: 8 December 2020; Published: 9 December 2020 Abstract: Mycoplasma bovis is an important pathogen causing mostly pneumonia in calves and mastitis in dairy cattle. In the absence of an effective vaccine, antimicrobial therapy remains the main control measure. Antimicrobial use in veal calves is substantially higher than in conventional herds, but whether veal calves also harbor more resistant M. bovis strains is currently unknown. Therefore, we compared antimicrobial susceptibility test results of M. bovis isolates from different cattle sectors and genomic clusters. The minimum inhibitory concentration of nine antimicrobials was determined for 141 Belgian M.
    [Show full text]